ITEK Inotek Pharmaceuticals Corporat

1.98
0  -4%
Previous Close 2.05
Open 2.05
Price To book 0.76
Market Cap 53.30M
Shares 26,986,000
Volume 848,572
Short Ratio 3.28
Av. Daily Volume 851,237

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 recruitment completed - noted April 11, 2017. Data due July 2017.
Trabodenoson and latanoprost
Glaucoma

Latest News

  1. Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
  2. Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost
  3. Inotek Pharmaceuticals Financial Review Potential Value Drivers and Drug Pipeline
  4. Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights
  5. Today's Research Reports on Biotech Stocks to Watch: Inotek Pharmaceuticals and Tetraphase Pharmaceuticals
  6. 24 HOUR DEADLINE NOTICE FOR ITEK INVESTORS: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  7. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
  8. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 - ITEK
  9. Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Inotek Pharmaceuticals Corporation Investors and Encourages Investors to Contact the Firm
  10. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
  11. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 – ITEK
  13. Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
  14. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  15. URGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders with Losses To Contact The Firm Immediately - ITEK
  16. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Inotek Pharmaceuticals Corporation to Contact the Firm Before Lead Plaintiff Deadline
  17. Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting
  18. EQUITY NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm